These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 15795559)
41. Thiazolidinediones as antidiabetic agents: A critical review. Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164 [TBL] [Abstract][Full Text] [Related]
42. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
43. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
44. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease. Bisgaier CL; Oniciu DC; Srivastava RAK J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036 [TBL] [Abstract][Full Text] [Related]
45. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice. Derosa G; Sahebkar A; Maffioli P J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353 [TBL] [Abstract][Full Text] [Related]
46. Statin islands and PPAR ligands in platelets. Phipps RP; Blumberg N Arterioscler Thromb Vasc Biol; 2009 May; 29(5):620-1. PubMed ID: 19369654 [No Abstract] [Full Text] [Related]
47. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Yessoufou A; Wahli W Swiss Med Wkly; 2010; 140():w13071. PubMed ID: 20842602 [TBL] [Abstract][Full Text] [Related]
48. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199 [TBL] [Abstract][Full Text] [Related]
51. Dissociation of oxidant production by peroxisome proliferator-activated receptor ligands from cell death in human cell lines. Atarod EB; Kehrer JP Free Radic Biol Med; 2004 Jul; 37(1):36-47. PubMed ID: 15183193 [TBL] [Abstract][Full Text] [Related]
52. [Relationship between insulin resistance and bone metabolism]. Hamada Y Clin Calcium; 2009 Sep; 19(9):1269-74. PubMed ID: 19721197 [TBL] [Abstract][Full Text] [Related]